<DOC>
	<DOCNO>NCT01371162</DOCNO>
	<brief_summary>This 2-part , randomize , double-blind , placebo-controlled study ass safety , pharmacokinetics pharmacodynamics RO5428029 healthy volunteer patient hepatitis C infection . Cohorts randomize receive either RO5428029 ascend dos placebo 7 day ( patient ) 14 day ( healthy volunteer ) .</brief_summary>
	<brief_title>A Study RO5428029 Healthy Volunteers Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Healthy subject ( Part A ) patient chronic hepatitis C infection ( Part B ) , 18 60 year age , inclusive Body mass index ( BMI ) 18 32 kg/m2 , inclusive , minimum weight 45 kg Female subjects/patients must surgically sterile postmenopausal Male subjects/patients partner childbearing potential must use 2 method contraception For HCV patient : Hepatitis C genotype 1 &gt; 6 month duration screen HCV RNA quantifiable ( Roche COBAS TaqMan HCV Test ) screen HCV treatmentna√Øve ( prior antiviral therapy chronic hepatitis C interferonbased therapy ) Liver biopsy noninvasive procedure within past 2 year show absence cirrhosis Pregnant lactate woman , male partner woman pregnant lactate Positive test drug abuse History ( within 3 month screen ) alcohol consumption exceed 2 standard drink per day average ( 1 standard drink = 10 gram 1 unit alcohol History symptom significant disease disorder History active malignancy within last 5 year , except localize situ carcinoma ( e.g . basal squamous cell carcinoma skin ) Positive hepatitis B HIV infection , and/ HCV healthy volunteer ( Part A ) For HCV patient : Decompensated liver disease impair liver function define history ascites , hepatic encephalopathy , hepatocellular carcinoma bleed esophageal varix , prothrombin international normalize ratio ( PTINR ) &gt; /= 2.0 screen Evidence cirrhosis and/or incomplete transition cirrhosis Presence history nonhepatitis C liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>